Nonetheless, we completely agree that randomized controlled clinical trials are needed to determine the ability of tumor mutational burden to predict responses to PD-1/PD-L1 checkpoint inhibitors, mainly in different tumor types. The gene discussed is CD274; the disease is neoplasm.